300 results about "Pyrone" patented technology

The present invention provides a pyrone derivative and a pyridone derivative, which are novel intermediates for synthesizing an anti-influenza drug, a method of producing the same, and a method of using the same.

The present invention relates to a pharmaceutical or veterinary or nutritional or personal care composition comprising coenzyme Q₁₀ (CoQ₁₀), reduced CoQ₁₀, or mixtures thereof and oxygenated dibenzo-α-pyrone or an amino acyl ester thereof. The composition of the present invention is able to support and/or provide therapy to individuals at risk and/or under treatment for dysfunctions of energy metabolism, and specifically, for mitochondrial diseases.

An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested/shown that C_20:5n-3 (and C_{22:6 n-3}) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.

The invention discloses a high-nicotine tobacco extract and application thereof, and belongs to the field of tobacco additives. The extract is rich in aroma components such as megastigmatrienone, damascone, pyrones and furanones in tobacco, can provide tobacco aroma and roasting aroma, further contains certain nicotine, can cater for physiological needs of consumers, and improves satisfaction. Content of macromolecular substances such as proteins, pectin and polysaccharides in the extract is extremely low, solubleness is good, the high-nicotine tobacco extract can be completely dissolved into MCT (medium chain triglyceride), and can be used for perfuming a filter tip. Besides, the high-nicotine tobacco extract is added into cut stems or reconstituted tobaccos, so that stimulus can be reduced, strength is improved, a blending rate, in a tobacco group, of the cut stems or reconstituted tobaccos is increased, and content of cigarette tar is reduced while fragrance is invigorated and impurities are covered.

The invention discloses a tobacco extract, an extracting method and application and belongs to the field of tobacco additives. The tobacco extract is extracted with the method including the following steps that firstly, propylene glycol is added into tobacco raw materials, and then baking is carried out after standing; secondly, smashing is carried out, and a solvent is added into powder materials for extraction; thirdly, extract liquid passes through an ultrafiltrtion membrane, penetrating liquid is obtained and subjected to reduced pressure distillation, and concentrate is obtained; fourthly, the concentrate is subjected to secondary separation with a molecule distillation method, light components are collected, and the tobacco extract is obtained. The extract contains rich megastigmatrienone, Damascone, neophytadiene, phenylcarbinol, phenethyl alcohol, farnesylacetone and pyrone and furanone aroma components, and the tobacco extract is thick in baking aroma and tobacco aroma, good in penetration, small in irritation and miscellaneous gas, high in satisfaction, capable of improving the smoking quality of cigarettes and providing a certain amount of nicotine to meet the physiological needs of consumers when used.

Methods and compositions are described that comprise pyrone analogs such as flavonoids and cyclodextrins including quercetin and quercetin derivatives and sulfoalkyl ether cyclodextrins. In some cases the compounds of the invention are administered with a therapeutic agent such as an analgesic. In some cases, treatment with the compositions of the invention can result in the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compositions out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compositions from physiological compartments, including central nervous system and fetal compartments.

The invention provides an essence microcapsule wall material for cigarettes. The material is a whey protein-glucose grafting product which is prepared through the maillard reaction of whey protein and glucose, wherein the mass ratio of the whey protein to glucose is 1:(1-3). The essence microcapsule wall material can generate heterocyclic compounds such as pyrazine, furan, pyrrole, pyrone and the like during combustion pyrolysis, and aroma components are harmony with the aroma of tobacco, so that adverse effects which are caused by adding a conventional wall material into the cigars are avoided. Moreover, an essence microcapsule prepared by the wall material has the advantages of uniform particles, dense capsule wall, high embedding rate, good stability, good releasing property and the like, and is suitable for various volatile cigar essences. In addition, the essence microcapsule prepared by the wall material has a certain releasing function, so that the essence durability can be prolonged, the phenomenon of strong aroma at the beginning and obviously weak aroma during a later period in a smoking process is avoided, and the essence microcapsule has strong practicability.

The invention discloses E-cigarette nicotine liquid and a preparation method thereof and belongs to the technical field of E-cigarette nicotine liquids. The E-cigarette nicotine liquid is made from high-nicotine tobacco extract, tobacco flavor and the like, wherein the tobacco extract has rich tobacco characteristic fragrant ingredients (such as megastigmatrienone, beta-damascone, pyrones, and furanones) and nicotine, can provide tobacco aroma and curing aroma and meet the physiological needs of consumers, and provides better satisfaction. The high-nicotine tobacco extract has very low contents of high-boiling-point ingredients and macromolecular substances (such as proteins, pectin, and polysaccharides), is free of burnt smell and low in sweetness, and can supplement aroma and cover peculiar odors, lower stimulus and improve taste strength. By being used with tobacco flavors, the E-cigarette nicotine liquid has enhanced curing aroma and tobacco aroma, and has strong aroma and good volatility. The preparation process of the E-cigarette nicotine liquid is simple, is simple and easy to perform, and is applicable to large-scale industrial production and application.

The present invention relates to compound with 6-aryl-3-substituted methylene-pyrone structure, derivative with 6-aryl-3-methyl-4-acryloxy tetrahydro pyrone skeleton, and their preparation process and use. Pharmacological activity test shows that the compound possesses acetylcholinesterase inhibiting activity and is expected to be used as medicine for senile dementia. The compound also shows relatively high activity of inhibiting tumor cells of prostate cancer, oral epithelium cancer, lung cancer and cervical cancer and thus is expected to be used as antitumor medicine.

The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents.

The present invention relates to a pyrone antibiotic, its preparation method and application. Its molecular formula is C10H16O2, and its molecular weight is 168. Said invention also provides its molecular structure diagram. Its preparation method includes the following steps: using solid culture medium to culture green trichoderma LTR-2, obtaining spore powder; soaking spore powder in dichloromethane with 5-10deg.C, making the soaking liquor successively undergo the processes of adsorption with active carbon, washing by using sodium sulfate solution, dehydration by using anhydrous sodium sulfate and reduced pressure concentration to obtain concentrate containing antibiotic pyrone. It can be used as effective component to prepare an agricultural preparation-wettability powder preparation whose composition includes diatomite, concentrate containing pyrone, sodium dodecyl benzene sulfonate and Tween 80.

Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.

Water-soluble, cell permeable aldose reductase inhibitors are presented. These compounds prevent the effects of galactosemia in patients. The compounds prevent both the accumulation of polyols and the change in levels of protein kinase C gamma observed during diabetes and galactosemia.

Provided are compounds of formula IA or IB:

wherein R1 and R8 are independently optionally substituted hydrocarbyl groups; wherein

• • (a) R1 contains a carbonyl group and a phenyl group,
  • (b) R8 contains an optionally substituted adenine group, or
  • (c) R8 contains an alkenyl group with from two to six carbon atoms;

R¹⁰ is H, —OH, —OR or ═O; R6 is selected from the group consisting of: H, OH, alkyl, alkenyl, alkynyl, an aromatic ring system, amino, sulfhydryl, sulfonyl, NH₂ and OCOR; R2 is selected from the group consisting of: H, —OH and lower alkyl; R is H or an optionally substituted hydrocarbyl group, and pharmaceutically acceptable salts or esters of the foregoing, as well as isomers thereof.

A composition of oxygenated dibenzo-alpha-pyrone chromoproteins (DCP) and their isolation from shilajit, fossils of ammonites, corals and other invertebrates. More particularly, to the description of DCP-composition comprising oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol and other small ligands, e.g., carotenoids, sterols and aromatic acids, as core structural fragments, and their biological functions. Pharmaceutical, nutritional, skin care and personal care formulations are also described. These findings establish DCPs as the major bioactives of shilajit.

The invention discloses an alpha-pyrone derivative, a preparation method and application thereof. The alpha-pyrone derivative is characterized by having a structural formula shown as I. The preparation method includes the steps of: using penicillium dipodomyicola with a preservation number of CCTCC No. M2014087 to conduct fermentation culture so as to obtain a fermentation product containing new alpha-pyrone derivative, then conducting methanol soaking and ethyl acetate extraction on the fermentation product to obtain a crude extract, and carrying out pressure reduction silica gel column chromatography and reversed-phase semi-preparative high performance liquid chromatography separation and purification on the crude extract, thus obtaining the alpha-pyrone derivative. The alpha-pyrone derivative has anti-Candida albicans effect, and can be used as a new pharmaceutical component or lead compound of a Candida albicans inhibitor.

A composition of oxygenated dibenzo-alpha-pyrone chromoproteins (DCP) and their isolation from shilajit, fossils of ammonites, corals and other invertebrates. More particularly, to the description of DCP-composition comprising oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol and other small ligands, e.g., carotenoids, sterols and aromatic acids, as core structural fragments, and their biological functions. Pharmaceutical, nutritional, skin care and personal care formulations are also described. These findings establish DCPs as the major bioactives of shilajit.

Described is a method of making sorbic acid, pentadiene, or 3-penten-2-one. The method includes partially hydrogenating 4-hydroxy-6-methyl-2-pyrone (HMP) to yield 5,6-dihydro-4-hydroxy-6-methyl-2H-pyran-2-one (4-DHMMP). Then, if 3-penten-2-one is desired, thermally decomposing the 4-DHMMP to yield 3-penten-2-one. If sorbic acid or pentadiene are desired, the 4-DHMMP is hydrogenated to yield 4-hydroxy-6-methyltetrahydro-2-pyrone (4-HMTHP). The 4-HMTHP is then dehydrated by contacting it with a solid acid catalyst to yield parasorbic acid (PSA). The PSA can then be ring-opened by contacting it with a solid acid catalyst. The reaction conditions of the ring-opening reaction can be controlled to yield sorbic acid and/or pentadiene.

The invention discloses an application of a benzo Alpha-pyrone compound as a Gamma-type human herpes virus-resistant medicine. According to the invention, the compound resistant to Gamma-type human herpes virus infection is higher in activity as compared with a novobiocin which is a marketed medicine, and is less in toxicity based on a cytoxicity test. The compound can be used for curing or preventing related diseases caused by KSHV infection.